Optimal Treatment Strategy for Amyloid A Amyloidosis in Rheumatic Diseases – Anti-Interleukin-6 Receptor Therapy

QR Code

Optimal Treatment Strategy for Amyloid A Amyloidosis in Rheumatic Diseases – Anti-Interleukin-6 Receptor Therapy

None

Saved in:

Bibliographic Details
Main Author:	Okuda, Yasuaki
Format:	Electronic Book Chapter
Language:	English
Published:	IntechOpen 2011
Subjects:	Health Sciences
Online Access:	https://www.intechopen.com/chapters/25474
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Presentation of Amyloid A Amyloidosis
by: Düzgün, Nurşen
Published: (2011)

New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
by: Evgeny Lvovich Nasonov
Published: (2013-10-01)

An Overview of the Amyloidosis in Children with Rheumatic Disease
by: Sözeri, Betül, et al.
Published: (2011)

Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis
by: Nakamura, Tadashi
Published: (2011)

INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
by: Evgeny Lvovich Nasonov, et al.
Published: (2013-12-01)

Interleukin 6 inhibition: new possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases
by: E L Nasonov, et al.
Published: (2013-11-01)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
by: Yasuaki Tomioka, et al.
Published: (2021-09-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Expression of Interleukin–6 and Interleukin-6 Receptor in Ovine Oocytes During In vitroMaturation
by: Xi-an ZHAO, et al.
Published: (2012-08-01)

The Association of Polymorphisms in Interleukin-6 (IL-6), Interleukin-10 (IL-10), IL-6 Receptor, and IL-10 Receptor Genes with the Risk of Pediatric Inflammatory Bowel Disease
by: Krawiec P, et al.
Published: (2025-06-01)

A case of effective use of interleukin 6 inhibitors in patients with ankylosing spondylitis with secondary amyloidosis
by: Sh. F. Erdes, et al.
Published: (2021-08-01)

Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
by: E. L. Nasonov, et al.
Published: (2022-05-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

AA-amyloidosis prevalence in rheumatic diseases (according to data of SI Institute of Rheumatology RAMS)
by: Y. V. Muravyov, et al.
Published: (2004-06-01)

Current and New Perspectives on the Molecular and Cellular Mechanisms of Amyloid Formation and Toxicity in Light Chain Amyloidosis
by: DiCostanzo, Ara Celi, et al.
Published: (2011)

Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
by: Shuta Ohara, et al.
Published: (2019-06-01)

Use of disease-modifying anti-rheumatic drugs in the therapy of osteoarthritis
by: S. G. Anikin, et al.
Published: (2019-05-01)

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
by: Emilie Gerard, et al.
Published: (2025-08-01)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
by: A. A. Baranov, et al.
Published: (2023-06-01)

Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders
by: T. A. Lisitsyna, et al.
Published: (2019-07-01)

Interrelation of the dynamics of serum concentrations of interleukin-1β, interleukin-6 and interleukin-10 with clinical data in acute ischemic stroke and the strategy of reperfusion therapy
by: A. Yu. Bykova, et al.
Published: (2020-01-01)

PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES
by: e L. Nasonov, et al.
Published: (2019-12-01)

Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
by: I. A. Mazerkina
Published: (2025-04-01)

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)

Surgical strategies for localized colorectal amyloidosis
by: Shunya Tahara, et al.
Published: (2023-04-01)

Dynamics of modified cardiovascular risk factors in patients with rheumatoid arthritis on the background of 5-year therapy with an interleukin 6 receptor inhibitor
by: E. V. Gerasimova, et al.
Published: (2024-03-01)

Therapy with non-steroidal anti-inflammatory drugs and the quality of life of patients with rheumatic diseases
by: E. Yu. Polishchuk, et al.
Published: (2022-02-01)

B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them.
by: E. V. Gerasimova, et al.
Published: (2019-01-01)

NEW OPPORTUNITIES OF TREATMENT OF DIFFERENT TYPES OF JUVENILE ARTHRITIS WITH MONOCLONAL ANTIBODIES TO THE INTERLEUKIN 6 RECEPTOR
by: E.I. Alexeeva, et al.
Published: (2010-01-01)

Resolution of the National Multidisciplinary Research Council of Experts on the place of anti-interleukin-6 receptor monoclonal antibodies (Sarilumab) in the treatment of patients with rheumatoid arthritis and comorbidity
by: article Editorial
Published: (2020-06-01)

Mediating role of Interleukin-6 in the predictive association of diabetes with Hippocampus atrophy, Amyloid, Tau, and Neurofilament pathology at pre-clinical stages of diabetes-related cognitive impairment
by: Asma Hallab, et al.
Published: (2025-08-01)

Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
by: Sagar S. Bachhav, et al.
Published: (2025-07-01)

Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects
by: Bong-Woo Lee, et al.
Published: (2025-07-01)

TARGETED THERAPY AND INFECTIONS IN RHEUMATIC DISEASES
by: B. S. Belov, et al.
Published: (2016-12-01)

Modern local therapy of rheumatic diseases
by: L. N. Denisov, et al.
Published: (2021-06-01)

ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS
by: L. P. Ananieva, et al.
Published: (2014-10-01)

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience
by: A. I. Zagrebneva, et al.
Published: (2022-12-01)

Interleukin-6 in the Breast Tumor Microenvironment
by: Sullivan, Nicholas J.
Published: (2011)

Interleukin 12: Stumbling Blocks and Stepping Stones to Effective Anti-Tumor Therapy
by: Pegram, Hollie J., et al.
Published: (2012)

Cardiometabolic risk factors and their relationship with the interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy
by: T. G. Bezhanishvili, et al.
Published: (2020-11-01)